Roche Holding AG logo

ROG - Roche Holding AG Share Price

CHF343.1 6.2  1.8%

Last Trade - 18/09/20

Large Cap
Market Cap £244.37bn
Enterprise Value £254.64bn
Revenue £51.16bn
Position in Universe 2nd / 1039
Unlock ROG Revenue
Relative Strength (%)
1m +6.04%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -5.85%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
47,462 48,145 50,576 53,299 56,846 61,466 61,906 64,697 +5.3%
-3.1 -8.5 +8.3 -0.8 +16.1 +16.4 +1.87 +6.33
Balance Sheet
FINANCIAL BRIEF: : For the six months ended 30 June 2020, Roche Holding AG revenues decreased 4% to SF29.28B. Net income decreased 6% to SF8.08B. Revenues reflect Roche Pharmaceuticals segment decrease of 4% to SF21.29B, Diagnostics segment decrease of 3% to SF6.08B, Chugai segment decrease of 4% to SF1.91B. Net income also reflects Roche Pharmaceuticals segment income decrease of 6% to SF8.9B, Diagnostics segment income decrease of 10% to SF865M.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for ROG
Graphical History


ROG Revenue Unlock ROG Revenue

Net Income

ROG Net Income Unlock ROG Revenue

Normalised EPS

ROG Normalised EPS Unlock ROG Revenue

PE Ratio Range

ROG PE Ratio Range Unlock ROG Revenue

Dividend Yield Range

ROG Dividend Yield Range Unlock ROG Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ROG EPS Forecasts Unlock ROG Revenue
Profile Summary

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated April 13, 1966
Public Since May 4, 2001
No. of Shareholders: n/a
No. of Employees: 97,735
Sector Healthcare
Industry Pharmaceuticals
Index FTSEurofirst 300 Pharmaceuticals & Biotechnology , FTSEurofirst 300 , FTSEurofirst 300 Ex Eurozone, FTSEurofirst 300 Ex UK, FTSE Global 100,
Exchange SIX Swiss Exchange (VTX)
Shares in Issue 854,641,595
Free Float (0.0%)
Eligible for
ROG Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for ROG
Upcoming Events for ROG
Wednesday 23rd September, 2020
Roche Holding AG at Baader Investment Conference (Virtual)
Thursday 24th September, 2020
Roche Holding AG at Sanford C Bernstein Strategic Decisions Conference
Wednesday 30th September, 2020
Roche Holding AG at Morningstar Management Behind the Moat Conference
Thursday 1st October, 2020
Roche Holding AG at JPMorgan Italian Conference
Thursday 15th October, 2020
Q3 2020 Roche Holding AG Corporate Sales Release
Thursday 15th October, 2020
Q3 2020 Roche Holding AG Corporate Sales Call
Monday 9th November, 2020
Roche Holding AG at Credit Suisse Healthcare Conference (Virtual)
Wednesday 11th November, 2020
Roche Holding AG at UBS European Conference
Monday 16th November, 2020
Roche Holding AG at Bryan Garnier European Healthcare Conference (Virtual)
Thursday 19th November, 2020
Roche Holding AG at Wolfe Research Healthcare Conference (Virtual)
Thursday 19th November, 2020
Roche Holding AG at Jefferies Healthcare Conference
Friday 27th November, 2020
Roche Holding AG Diagnostics Day (Buy-Side)
Wednesday 2nd December, 2020
Roche Holding AG at Societe Generale Premium Review Conference
Wednesday 2nd December, 2020
Roche Holding AG at Evercore ISI MedTools Conference
Thursday 3rd December, 2020
Roche Holding AG at Berenberg European Conference (Virtual)
Sunday 13th December, 2020
Roche Holding AG AACC - Analyst Event
Thursday 28th January, 2021 Estimate
Full Year 2020 Roche Holding AG Earnings Release
Tuesday 16th March, 2021
Roche Holding AG Annual Shareholders Meeting
Frequently Asked Questions for Roche Holding AG
What is the Roche Holding AG share price?

As of 18/09/20, shares in Roche Holding AG are trading at CHF343.1, giving the company a market capitalisation of £244.37bn. This share price information is delayed by 15 minutes.

How has the Roche Holding AG share price performed this year?

Shares in Roche Holding AG are currently trading at CHF343.1 and the price has moved by 19.66% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Roche Holding AG price has moved by 27.37% over the past year.

What are the analyst and broker recommendations for Roche Holding AG?

Of the analysts with advisory recommendations for Roche Holding AG, there are there are currently 2 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Roche Holding AG is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Roche Holding AG next release its financial results?

Roche Holding AG is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Roche Holding AG dividend yield?

The Roche Holding AG dividend yield is 2.67% based on the trailing twelve month period.

Does Roche Holding AG pay a dividend?

Last year, Roche Holding AG paid a total dividend of 9, and it currently has a trailing dividend yield of 2.67%. Looking ahead, Roche Holding AG has not announced an ex-dividend date yet.

When does Roche Holding AG next pay dividends?

Roche Holding AG has yet to annouce their ex-dividend date. The historic dividend yield on Roche Holding AG shares is currently 2.67%.

How do I buy Roche Holding AG shares?

To buy shares in Roche Holding AG you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Roche Holding AG?

Shares in Roche Holding AG are currently trading at CHF343.1, giving the company a market capitalisation of £244.37bn.

Where are Roche Holding AG shares listed? Where are Roche Holding AG shares listed?

Here are the trading details for Roche Holding AG:

Country of listing: Switzerland
Exchange: VTX
Ticker Symbol: ROG
What kind of share is Roche Holding AG?

Based on an overall assessment of its quality, value and momentum, Roche Holding AG is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Roche Holding AG share price forecast 2020?

Shares in Roche Holding AG are currently priced at CHF343.1. At that level they are trading at 13.88% discount to the analyst consensus target price of 0.00.

Analysts covering Roche Holding AG currently have a consensus Earnings Per Share (EPS) forecast of 18.622 for the next financial year.

How can I tell whether the Roche Holding AG share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Roche Holding AG. Over the past six months, the relative strength of its shares against the market has been -12.15%. At the current price of CHF343.1, shares in Roche Holding AG are trading at 3.75% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Roche Holding AG PE Ratio?

The Roche Holding AG PE ratio based on its reported earnings over the past 12 months is 19.45. The shares are currently trading at CHF343.1.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Roche Holding AG?

Roche Holding AG's management team is headed by:

Fritz Gerber - NEC
Andre Hoffmann - NVC
Severin Schwan - CMG
Christoph Franz - NEC
Alan Hippe - CFO
Cristina Wilbur - CHO
William Anderson - EXB
William Pao - EXB
James Sabry - EXB
Thomas Schinecker - EXB
Barbara Schaedler - EXB
Hans Clevers - DRC
Claudia Boeckstiegel - GCN
Pascale Schmidt - CCO
Joerg Duschmale - DRC
Who are the major shareholders of Roche Holding AG?

Here are the top five shareholders of Roche Holding AG based on the size of their shareholding:

The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 3.05% (21.4m shares)
Statens Pensjonsfond Utland Mutual Fund
Percentage owned: 2.76% (19.4m shares)
Norges Bank Investment Management (NBIM) Sovereign Wealth Fund
Percentage owned: 2.76% (19.4m shares)
Fidelity Management & Research Company LLC Investment Advisor
Percentage owned: 1.82% (12.8m shares)
Vanguard Total International Stock Index Fund Mutual Fund
Percentage owned: 1.68% (11.8m shares)
Similar to ROG
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.